Multiple Myeloma

7 protocols meet the specified criteria.

  • BMTCTN1704

    Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)

  • EA9171

    Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

  • EAA173

    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

  • PRE0905

    Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  • S1803

    Phase III Study of Daratumumab/rHuPH20 (NSC-810304) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.

  • STRO-001-BCM1

    A Phase I Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients with Advanced B-Cell Malignancies